Affinity Asset Advisors logo

Affinity Asset Advisors

North America, New York, United States, New York

Description

Affinity Asset Advisors is a healthcare-focused hedge fund with public and private investments

Investor Profile

Affinity Asset Advisors has backed more than 11 startups, with 1 new investments in the last 12 months alone. The firm has led 2 rounds, about 18% of its total and boasts 5 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series A, Series D rounds (top funding stages).
  • Majority of deals are located in United States, Canada, Singapore.
  • Strong thematic focus on Biotechnology, Therapeutics, Health Care.

Stage Focus

  • Post Ipo Equity (45%)
  • Series A (18%)
  • Series D (9%)
  • Series C (9%)
  • Series B (9%)
  • Series Unknown (9%)

Country Focus

  • United States (82%)
  • Canada (9%)
  • Singapore (9%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Life Science
  • Clinical Trials
  • Computer
  • Medical Device
  • Health Diagnostics
  • Neuroscience
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Affinity Asset Advisors frequently co-invest with?

Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 2
Altium Capital
North America, New York, United States, New York
Co-Investments: 2
Woodline Partners
North America, California, United States, San Francisco
Co-Investments: 2
Braidwell
North America, Connecticut, United States, Stamford
Co-Investments: 2
RTW Investments
North America, New York, United States, New York
Co-Investments: 2
Ally Bridge Group
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 3
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 2
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 2
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 2
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 2

What are some of recent deals done by Affinity Asset Advisors?

Sol-Gel Technologies

Nes Ziyyona, HaMerkaz, Israel

Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals.

BiotechnologyPharmaceutical
Post Ipo EquityMar 23, 2026
Amount Raised: $33,100,000
Ovid Therapeutics

New York, New York, United States

Ovid Therapeutic's purpose is to solve intractable medical problems.

BiopharmaBiotechnologyHealth Care
Post Ipo EquityMar 17, 2026
Amount Raised: $60,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityMar 9, 2026
Amount Raised: $85,000,000
MedinCell

Jacou, Languedoc-Roussillon, France

MedinCell is an injectable slow-release drug specialist company.

Pharmaceutical
Post Ipo EquityMar 5, 2026
Amount Raised: $55,745,827
Perspective Therapeutics

Seattle, Washington, United States

Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.

Health CareMedicalTherapeutics
Post Ipo EquityFeb 2, 2026
Amount Raised: $175,000,000
TRex Bio

South San Francisco, California, United States

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

BioinformaticsBiopharmaBiotechnology
Series UnknownJan 27, 2026
Amount Raised: $50,000,000
Odyssey Therapeutics

Cambridge, Massachusetts, United States

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

BiotechnologyHealth CareOncologyTherapeutics
Series DSep 10, 2025
Amount Raised: $213,000,000
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Post Ipo EquityMay 27, 2025
Amount Raised: $80,000,000
Spyre Therapeutics

San Francisco, California, United States

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

BiotechnologyTherapeutics
Post Ipo EquityDec 7, 2023
Amount Raised: $180,000,000
Tourmaline Bio

New York, New York, United States

Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve and prevent immune diseases.

BiotechnologyClinical TrialsTherapeutics
Post Ipo EquityOct 19, 2023
Amount Raised: $75,000,000

Find More Investors Like Affinity Asset Advisors

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

Affinity Asset Advisors | Pipeseed